These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 1316826)
1. Overrunning and underrunning in sequential clinical trials. Whitehead J Control Clin Trials; 1992 Apr; 13(2):106-21. PubMed ID: 1316826 [TBL] [Abstract][Full Text] [Related]
2. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials. Englert S; Kieser M Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860 [TBL] [Abstract][Full Text] [Related]
3. Overrunning in clinical trials: some thoughts from a methodological review. Baldi I; Azzolina D; Soriani N; Barbetta B; Vaghi P; Giacovelli G; Berchialla P; Gregori D Trials; 2020 Jul; 21(1):668. PubMed ID: 32693832 [TBL] [Abstract][Full Text] [Related]
4. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Lachin JM Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716 [TBL] [Abstract][Full Text] [Related]
5. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning. Schmidt R; Burkhardt B; Faldum A Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500 [TBL] [Abstract][Full Text] [Related]
6. Sequential stopping rules in clinical trials. McPherson K Stat Med; 1990 Jun; 9(6):595-600. PubMed ID: 2218163 [TBL] [Abstract][Full Text] [Related]
7. Study duration for clinical trials with survival response and early stopping rule. Kim K; Tsiatis AA Biometrics; 1990 Mar; 46(1):81-92. PubMed ID: 2350572 [TBL] [Abstract][Full Text] [Related]
8. A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events. Kashiwabara K; Matsuyama Y; Ohashi Y Ther Innov Regul Sci; 2014 Jul; 48(4):444-452. PubMed ID: 30235573 [TBL] [Abstract][Full Text] [Related]
9. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Emerson SS Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699 [TBL] [Abstract][Full Text] [Related]
10. On the frequentist and likelihood controversy over sequential stopping rules in clinical trials. Herson J Control Clin Trials; 1983 Sep; 4(3):261-3. PubMed ID: 6641238 [No Abstract] [Full Text] [Related]
11. Interim analyses and stopping rules in cancer clinical trials. Whitehead J Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370 [TBL] [Abstract][Full Text] [Related]
12. A practical guide to Bayesian group sequential designs. Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922 [TBL] [Abstract][Full Text] [Related]
14. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis. Jahn-Eimermacher A; Hommel G Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553 [TBL] [Abstract][Full Text] [Related]
16. Sequential clinical trials in cancer research. George SL Cancer Treat Rep; 1980; 64(2-3):393-7. PubMed ID: 7407775 [TBL] [Abstract][Full Text] [Related]
17. Frequentist evaluation of group sequential clinical trial designs. Emerson SS; Kittelson JM; Gillen DL Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678 [TBL] [Abstract][Full Text] [Related]
18. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. Wang H; Rosner GL; Goodman SN Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682 [TBL] [Abstract][Full Text] [Related]
19. Issues in the use of adaptive clinical trial designs. Emerson SS Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553 [TBL] [Abstract][Full Text] [Related]
20. Group sequential clinical trials with triangular continuation regions. Whitehead J; Stratton I Biometrics; 1983 Mar; 39(1):227-36. PubMed ID: 6871351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]